<DOC>
	<DOCNO>NCT02557932</DOCNO>
	<brief_summary>In randomize controlled trial , investigate effect 10-day bismuth quadruple therapy comparison 7-day PPI-based standard triple 1st line treatment H. pylorus .</brief_summary>
	<brief_title>Comparison 7-day PPI-based Standard Triple Therapy 10-day Bismuth Quadruple Therapy H. Pylori Eradication</brief_title>
	<detailed_description>Current Helicobacter pylorus management guideline recommend proton-pump inhibitor ( PPI ) -Clarithromycin contain triple therapy 1st line treatment . However , Korea , eradication rate PPI-Clarithromycin contain triple therapy decrease less 80 % due increase clarithromycin resistance . In area high clarithromycin resistance ( resistance rate 15 % ) , guideline recommend bismuth quadruple therapy 1st line treatment H. pylorus eradication . Clarithromycin resistance rate report 15.7 % 42.1 % Korea , thus , bismuth quadruple therapy may better 1st line treatment PPI-Clarithromycin contain triple therapy . However , one limit study perform compare effect treatment regimens Korea . Thus , study evaluate effect 10-day bismuth quadruple therapy first line treatment H. pylorus infection .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Men woman age 18 Family history gastric cancer H. pylori positive urea breath test History H. pylorus eradication therapy History stomach operation Other organ cancer within 5 year Liver cirrhosis Hepatic insufficiency Renal insufficiency Current treatment serious medical condition may hinder participation Contraindication allergy history H. pylorus treatment regimens Mental incompetence understand sign inform consent Incompatible condition include trial investigator ' decision Inability provide inform consent History treatment peptic ulcer disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PPI standard triple therapy</keyword>
	<keyword>Bismuth quadruple therapy</keyword>
	<keyword>Helicobacter</keyword>
</DOC>